U.S. rulings on CAT/MOR

MorphoSys (NMarkt:MOR) said a judge in the U.S. District Court in Washington, D.C. issued a preliminary ruling related to MOR's suit seeking a determination that it does not infringe Cambridge Antibody Technology's "Griffiths" patent (U.S. Patent No. 5,885,793) and that the patent is invalid. The judge determined that " MorphoSys should prevail on the issue of infringement" because "no reasonable jury could find that the HuCAL library, whose starting point is theoretical analysis of data, is 'derived from a human.'" The issue has been a central point of contention in the suit, but the judge added that he would allow Cambridge Antibody (LSE:CAT; CATG) to make its case in an additional briefing before making his final decision. The briefing is yet to be scheduled. The judge also dismissed all but one of MOR's arguments in favor of invalidity. ...